# Diffuse Large B-cell Lymphoma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/diffuse-large-b-cell-lymphoma

> 12 upcoming FDA catalysts in diffuse Large B-cell Lymphoma: XPOVIO® (selinexor, KPTIQ) on December 2026 (primary completion); XPOVIO® (selinexor, KPTIQ) on Dec 2026 to Mar 2027 (topline data readout); Calquence (acalabrutinib, AZN) on Feb to May 2027 (topline data readout); Calquence (acalabrutinib, AZN) on February 2027 (primary completion); and 8 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 13, 2025 | [TEPKINLY (epcoritamab) primary completion](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-cell Lymphoma | completed | "NCT04628494 (A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Genmab; Results First Posted 2026-11-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04628494)) |
| October 13, 2025 | [TEPKINLY (epcoritamab) primary completion](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-Cell Lymphoma | completed | "NCT07226752 (A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Genmab; Results First Posted 2026-11-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226752)) |
| January 23, 2026 | [Brentuximab vedotin primary completion](https://sec-api.dev/pdufa/brentuximab-vedotin) | PFE | Diffuse Large B-cell Lymphoma | completed | "NCT04404283 (Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-23 (ACTUAL); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer; Results First Posted 2026-10-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04404283)) |
| June 10, 2026 | [TEPKINLY (epcoritamab) primary completion](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-Cell Lymphoma | withdrawn | "NCT05660967 (Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-06-10 (ACTUAL); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05660967)) |
| September 2026 | [MINJUVI (tafasitamab) primary completion](https://sec-api.dev/pdufa/tafasitamab) | INCY | Diffuse Large B-cell Lymphoma | delayed | "NCT04824092 (Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-01 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04824092)) |
| Sep to Dec 2026 | [MINJUVI (tafasitamab) topline data readout](https://sec-api.dev/pdufa/tafasitamab) | INCY | Diffuse Large B-cell Lymphoma | scheduled | "NCT04824092 (Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-01 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04824092)) |
| October 21, 2026 | [Brentuximab vedotin topline data readout](https://sec-api.dev/pdufa/brentuximab-vedotin) | PFE | Diffuse Large B-cell Lymphoma | completed | "NCT04404283 (Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-23 (ACTUAL); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer; Results First Posted 2026-10-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04404283?tab=results)) |
| November 3, 2026 | [TEPKINLY (epcoritamab) topline data readout](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-cell Lymphoma | completed | "NCT04628494 (A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Genmab; Results First Posted 2026-11-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04628494?tab=results)) |
| November 10, 2026 | [TEPKINLY (epcoritamab) topline data readout](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-Cell Lymphoma | completed | "NCT07226752 (A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Genmab; Results First Posted 2026-11-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226752?tab=results)) |
| December 2026 | [XPOVIO® (selinexor) primary completion](https://sec-api.dev/pdufa/selinexor) | KPTIQ | Diffuse Large B-cell Lymphoma | scheduled | "NCT02227251 (Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Karyopharm Therapeutics Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02227251)) |
| Dec 2026 to Mar 2027 | [XPOVIO® (selinexor) topline data readout](https://sec-api.dev/pdufa/selinexor) | KPTIQ | Diffuse Large B-cell Lymphoma | scheduled | "NCT02227251 (Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Karyopharm Therapeutics Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02227251)) |
| Feb to May 2027 | [Calquence (acalabrutinib) topline data readout](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Diffuse Large B-Cell Lymphoma | scheduled | "NCT04529772 (A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-22 (ESTIMATED); Lead Sponsor Acerta Pharma BV." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04529772)) |
| February 2027 | [Calquence (acalabrutinib) primary completion](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Diffuse Large B-Cell Lymphoma | scheduled | "NCT04529772 (A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-22 (ESTIMATED); Lead Sponsor Acerta Pharma BV." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04529772)) |
| June 2027 | [TEPKINLY (epcoritamab) primary completion](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-Cell Lymphoma | scheduled | "NCT05578976 (A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05578976)) |
| Jun to Sep 2027 | [TEPKINLY (epcoritamab) topline data readout](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-Cell Lymphoma | scheduled | "NCT05578976 (A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05578976)) |
| March 2028 | [TEPKINLY (epcoritamab) primary completion](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-Cell Lymphoma | scheduled | "NCT06508658 (A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06508658)) |
| Mar to Jun 2028 | [TEPKINLY (epcoritamab) topline data readout](https://sec-api.dev/pdufa/epcoritamab) | GMAB | Diffuse Large B-Cell Lymphoma | scheduled | "NCT06508658 (A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06508658)) |
| Apr to Jul 2029 | [Calquence (acalabrutinib) topline data readout](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Diffuse Large B-Cell Lymphoma | scheduled | "NCT05952024 (Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-04-22 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05952024)) |
| April 2029 | [Calquence (acalabrutinib) primary completion](https://sec-api.dev/pdufa/acalabrutinib) | AZN | Diffuse Large B-Cell Lymphoma | scheduled | "NCT05952024 (Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-04-22 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05952024)) |
| Jul to Oct 2029 | [Zilovertamab vedotin topline data readout](https://sec-api.dev/pdufa/zilovertamab-vedotin) | MRK | Diffuse Large B-Cell Lymphoma | scheduled | "NCT06717347 (A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-02 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06717347)) |
| July 2029 | [Zilovertamab vedotin primary completion](https://sec-api.dev/pdufa/zilovertamab-vedotin) | MRK | Diffuse Large B-Cell Lymphoma | scheduled | "NCT06717347 (A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-02 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06717347)) |

## Drugs

- [TEPKINLY (epcoritamab)](https://sec-api.dev/pdufa/epcoritamab) (GMAB)
- [Brentuximab vedotin](https://sec-api.dev/pdufa/brentuximab-vedotin) (PFE)
- [MINJUVI (tafasitamab)](https://sec-api.dev/pdufa/tafasitamab) (INCY)
- [XPOVIO® (selinexor)](https://sec-api.dev/pdufa/selinexor) (KPTI)
- [Calquence (acalabrutinib)](https://sec-api.dev/pdufa/acalabrutinib) (AZN)
- [Zilovertamab vedotin](https://sec-api.dev/pdufa/zilovertamab-vedotin) (MRK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/diffuse-large-b-cell-lymphoma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Diffuse Large B-cell Lymphoma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/diffuse-large-b-cell-lymphoma

```bibtex
@misc{secapidev_indications_diffuse_large_b_cell_lymphoma_20261116,
  title        = {Diffuse Large B-cell Lymphoma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/diffuse-large-b-cell-lymphoma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_diffuse_large_b_cell_lymphoma_20261116","title":"Diffuse Large B-cell Lymphoma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/diffuse-large-b-cell-lymphoma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
